{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sannaa W"],"funding":["NIDDK NIH HHS","National Institutes of Health"],"pagination":["377-386"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9812862"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(2)"],"pubmed_abstract":["<h4>Aim</h4>To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.<h4>Methods</h4>One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily. Gastrointestinal functions were measured at baseline and 16 weeks: gastric emptying of solids (GET<sub>1/2</sub> ); fasting and postprandial gastric volumes; kcal ingested during ad libitum buffet meal and the nutrient drink test. GET<sub>1/2</sub> was also measured at 5 weeks. A multiple variable regression model examined variables associated with weight loss of more than 4 kg at 16 week"],"journal":["Diabetes, obesity & metabolism"],"pubmed_title":["Factors associated with successful weight loss after liraglutide treatment for obesity."],"pmcid":["PMC9812862"],"funding_grant_id":["R01‐DK67071","R01 DK067071"],"pubmed_authors":["Dilmaghani S","Camilleri M","Maselli D","Harmsen WS","BouSaba J","Sannaa W","Eckert D","Taylor AL","Atieh J","Acosta A"],"additional_accession":[]},"is_claimable":false,"name":"Factors associated with successful weight loss after liraglutide treatment for obesity.","description":"<h4>Aim</h4>To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.<h4>Methods</h4>One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily. Gastrointestinal functions were measured at baseline and 16 weeks: gastric emptying of solids (GET<sub>1/2</sub> ); fasting and postprandial gastric volumes; kcal ingested during ad libitum buffet meal and the nutrient drink test. GET<sub>1/2</sub> was also measured at 5 weeks. A multiple variable regression model examined variables associated with weight loss of more than 4 kg at 16 week","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T11:53:46.86Z","creation":"2025-02-19T04:59:43.509Z"},"accession":"S-EPMC9812862","cross_references":{"pubmed":["36193713"],"doi":["10.1111/dom.14880"]}}